Herein, mesoporous silicon particles (PSiP) were assessed as carriers for a peptide-based vaccine targeting the receptor for advanced glycation end products (RAGE), which is a relevant receptor in Alzheimer ́s disease and other diseases. This evidence concerns the gene AGER and early-onset autosomal dominant Alzheimer disease.